CN114432283A - Sirtinol在制备预防和治疗冠状病毒的药物中的应用 - Google Patents
Sirtinol在制备预防和治疗冠状病毒的药物中的应用 Download PDFInfo
- Publication number
- CN114432283A CN114432283A CN202011188930.6A CN202011188930A CN114432283A CN 114432283 A CN114432283 A CN 114432283A CN 202011188930 A CN202011188930 A CN 202011188930A CN 114432283 A CN114432283 A CN 114432283A
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- coronavirus
- sirtinol
- cov
- sars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 59
- UXJFDYIHRJGPFS-WPWMEQJKSA-N chembl380797 Chemical compound C=1C=CC=C(\N=C\C=2C3=CC=CC=C3C=CC=2O)C=1C(=O)NC(C)C1=CC=CC=C1 UXJFDYIHRJGPFS-WPWMEQJKSA-N 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 229940002612 prodrug Drugs 0.000 claims abstract description 16
- 239000000651 prodrug Substances 0.000 claims abstract description 16
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 12
- 150000001408 amides Chemical class 0.000 claims abstract description 12
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 11
- 244000309467 Human Coronavirus Species 0.000 claims abstract description 8
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims abstract description 8
- 208000015181 infectious disease Diseases 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- -1 acemenan Chemical compound 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 7
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 6
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 claims description 6
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 3
- OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 claims description 3
- KCURWTAZOZXKSJ-JBMRGDGGSA-N 4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydron;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 KCURWTAZOZXKSJ-JBMRGDGGSA-N 0.000 claims description 3
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 claims description 3
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 3
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 3
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims description 3
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 3
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 3
- IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 claims description 3
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 claims description 3
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 claims description 3
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 claims description 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 3
- 229960004748 abacavir Drugs 0.000 claims description 3
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims description 3
- 229960004150 aciclovir Drugs 0.000 claims description 3
- 229940008235 acyclovir sodium Drugs 0.000 claims description 3
- 229960001997 adefovir Drugs 0.000 claims description 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 3
- 229950004424 alovudine Drugs 0.000 claims description 3
- 229960003805 amantadine Drugs 0.000 claims description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
- 229960000724 cidofovir Drugs 0.000 claims description 3
- MEPNHSOMXMALDZ-UHFFFAOYSA-N delavirdine mesylate Chemical compound CS(O)(=O)=O.CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 MEPNHSOMXMALDZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000475 delavirdine mesylate Drugs 0.000 claims description 3
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 claims description 3
- 229950000330 desciclovir Drugs 0.000 claims description 3
- 229960002656 didanosine Drugs 0.000 claims description 3
- QGXLVXZRPRRCRP-MMGZGRSYSA-L disodium;[(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H]1O QGXLVXZRPRRCRP-MMGZGRSYSA-L 0.000 claims description 3
- 229960000366 emtricitabine Drugs 0.000 claims description 3
- 229960002963 ganciclovir Drugs 0.000 claims description 3
- 229960002687 ganciclovir sodium Drugs 0.000 claims description 3
- 229960001936 indinavir Drugs 0.000 claims description 3
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
- 229960001627 lamivudine Drugs 0.000 claims description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 3
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 claims description 3
- 229960000884 nelfinavir Drugs 0.000 claims description 3
- 229960000689 nevirapine Drugs 0.000 claims description 3
- 229960003752 oseltamivir Drugs 0.000 claims description 3
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 3
- 150000002923 oximes Chemical class 0.000 claims description 3
- 229960001179 penciclovir Drugs 0.000 claims description 3
- 229960000329 ribavirin Drugs 0.000 claims description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 3
- 229960000888 rimantadine Drugs 0.000 claims description 3
- 229960000311 ritonavir Drugs 0.000 claims description 3
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 3
- 229960003542 saquinavir mesylate Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229960001203 stavudine Drugs 0.000 claims description 3
- 229960004556 tenofovir Drugs 0.000 claims description 3
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 3
- 229960000838 tipranavir Drugs 0.000 claims description 3
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 claims description 3
- 229940064636 valacyclovir hydrochloride Drugs 0.000 claims description 3
- 229960000523 zalcitabine Drugs 0.000 claims description 3
- 229960002555 zidovudine Drugs 0.000 claims description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
- KCHIOGFOPPOUJC-UHFFFAOYSA-N (methylpyridazine piperidine ethyloxyphenyl)ethylacetate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCC1CCN(C=2N=NC(C)=CC=2)CC1 KCHIOGFOPPOUJC-UHFFFAOYSA-N 0.000 claims description 2
- IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 claims description 2
- RMJPDSDRGGRKTH-UHFFFAOYSA-N 2-ethoxybutanal Chemical compound CCOC(CC)C=O RMJPDSDRGGRKTH-UHFFFAOYSA-N 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 2
- UDMBCSSLTHHNCD-UHTZMRCNSA-N [(2r,3s,4s,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O UDMBCSSLTHHNCD-UHTZMRCNSA-N 0.000 claims description 2
- 229960000848 foscarnet sodium Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims description 2
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 2
- 229940049954 penicillin Drugs 0.000 claims description 2
- 229950011136 pirodavir Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 claims description 2
- 229950007412 viroxime Drugs 0.000 claims description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 claims 2
- WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 claims 2
- 229950010555 avridine Drugs 0.000 claims 2
- 229960004396 famciclovir Drugs 0.000 claims 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims 2
- 229960000443 hydrochloric acid Drugs 0.000 claims 2
- 229960004525 lopinavir Drugs 0.000 claims 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 1
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 claims 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 1
- 229950006790 adenosine phosphate Drugs 0.000 claims 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 claims 1
- 229960001280 amantadine hydrochloride Drugs 0.000 claims 1
- 229960000354 fexofenadine hydrochloride Drugs 0.000 claims 1
- 229960004716 idoxuridine Drugs 0.000 claims 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 claims 1
- 229960000967 memantine hydrochloride Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940083542 sodium Drugs 0.000 claims 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims 1
- 229960003636 vidarabine Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 36
- 239000002245 particle Substances 0.000 description 21
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 12
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 12
- 241001112090 Pseudovirus Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 238000003125 immunofluorescent labeling Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102100031673 Corneodesmosin Human genes 0.000 description 5
- 101710139375 Corneodesmosin Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102100021696 Syncytin-1 Human genes 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 241001573881 Corolla Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VPXSYLFGBHFLCF-VWZUFWLJSA-N 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione hydrochloride Chemical compound C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O.Cl VPXSYLFGBHFLCF-VWZUFWLJSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000112287 Bat coronavirus Species 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 101710121925 Hemagglutinin glycoprotein Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 229950010415 givinostat Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 108010028403 hemagglutinin esterase Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011452 sequencing regimen Methods 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及SIRTINOL在制备预防和治疗冠状病毒的药物中的应用。具体公开了SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备预防和治疗冠状病毒所致疾病的药物中的应用。所述的冠状病毒为新型冠状病毒SARS‑Cov‑2、SARS‑CoV、HCoV 229E、NL63、OC43、HKU1和MERS‑CoV。冠状病毒所致疾病为SARS‑Cov‑2、SARS‑CoV、HCoV 229E、NL63、OC43、HKU1或MERS‑CoV任一病毒引起的肺炎或其并发症。本发明首次证实了SIRTINOL对新冠肺炎新型冠状病毒抑制作用,半数有效浓度低,具有极大潜力。
Description
技术领域
本发明属于药物领域,具体涉及SIRTINOL在制备预防和治疗冠状病毒的药物中的应用。
背景技术
新型冠状病毒肺炎(Corona Virus Disease 2019)是由新型冠状病毒(SARS-Cov-2)感染人体而引起的传染性疾病,其症状主要包括发热、乏力、干咳、呼吸困难和肾衰竭等[TheLancet,2020,395(10223):507-513;The Lancet,2020,395(10223):497-506]。冠状病毒在系统分类上属冠状病毒科(Coronaviridae)冠状病毒属(Corona virus)。冠状病毒属的病毒是具外套膜(envelope)的正链单股RNA病毒,直径约80~120nm,其遗传物质是所有RNA病毒中最大的,一般只会感染人、鼠、猪、猫、犬、禽类脊椎动物。冠状病毒于1937年被首次从鸡身上分离出来。冠状病毒粒子形状并不规则,直径约60~220nm。病毒具有包膜结构,上面有三种蛋白:刺突糖蛋白(S,Spike Protein)、小包膜糖蛋白(E,Envelope Protein)和膜糖蛋白(M,Membrane Protein),少数种类还有血凝素糖蛋白(HE蛋白,Haemaglutinin-esterase)[Nederlands Tijdschrift Voor Geneeskunde,2014,158(158):A8119-A8119]。
SARS-Cov-2病毒颗粒直径在60~140nm之间,包膜外有9~12nm的尖刺,形似花冠。基因组测序表明,SARS-Cov-2是一种单链RNA冠状病毒。通过与其他病毒样品基因序列的比较,发现SARS-Cov-2与SARS-CoV(79.5%)[Nature,2020]和蝙蝠冠状病毒(96%)相似[bioRxiv,2020,2020.01.22.914952],并推测该病毒可能起源于蝙蝠[bioRxiv,2020,2020.01.24.915157;Nature,2020]。2019-nCoV病毒属于βCoV,是区别于SARS-CoV和MERS-CoV的HCoV家族的第7个成员[New England Journal of Medicine,2020],其余6个成员包括HCoV 229E、NL63、OC43、HKU1、SARS-CoV和MERS-CoV。
引起新型冠状病毒肺炎的是一种新型冠状病毒,它与人们熟知的引起非典型性肺炎的SARS-CoV同属冠状病毒,但类型不同,其致死率虽低于SARS-CoV但传染性远远高于SARS-CoV。
SIRTINOL(Givinostat)是一种是sirtuin(SIRT)的抑制剂,对ySir2,hSIRT2和hSIRT2的IC50值分别为48μM,57.7μM和131μM。
但是,到目前为止依旧没有任何特效药物能够治愈新型冠状病毒肺炎。目前的治疗方法大多是对症治疗,特别是对一些重症患者疗效较差。因此,开发有效的冠状病毒肺炎治疗特效药物成为了当下一个迫在眉睫需要解决的课题。
发明内容
本发明的目的在于提供SIRTINOL在制备预防或治疗抗新冠肺炎新型冠状病毒的药物中的应用。
具体而言,为解决的本发明的技术问题,采用如下技术方案:
本发明提供了SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。
本发明另一个方面提供了SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备阻止冠状病毒进入细胞的药物中的应用。
在本发明的技术方案中,所述的冠状病毒为新型冠状病毒SARS-Cov-2、SARS-CoV、HCoV 229E、NL63、OC43、HKU1和MERS-CoV。
在本发明的技术方案中,冠状病毒所致疾病为SARS-Cov-2、SARS-CoV、HCoV 229E、NL63、OC43、HKU1或MERS-CoV任一病毒引起的肺炎或其并发症。
在本发明的技术方案中,SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药作为唯一活性成分在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。
在本发明的技术方案中,SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药与其他抗病毒药物制备的组合物作为活性成分在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。
在本发明的技术方案中,其他抗病毒药物选自更昔洛韦、阿昔洛韦、金刚烷胺、金刚乙胺、奥司他韦、阿巴卡韦、醋孟南、阿昔洛韦钠、阿德福韦、阿洛夫定、阿韦舒托、盐酸三环癸胺、阿拉诺丁、阿立酮、阿替韦啶甲磺酸酯、阿夫立定、西多福韦、西潘茶碱、恩曲他滨、盐酸阿糖胞苷、甲磺酸地拉韦啶、地昔洛韦、去羟肌苷、二噁沙利、依度尿苷、乙米韦林、依曲西他平、恩韦拉登、恩韦肟、贺普丁、泛昔洛韦、盐酸氯苯氢异喹、非西他滨、非阿尿苷、磷利酯、膦甲酸钠、膦乙酸钠、甘西洛维钠、碘苷、茚地那韦、乙氧丁酮醛、拉米夫定、洛布卡韦、洛德腺苷、洛匹那韦、盐酸美莫汀、甲红硫脲、那非那韦、奈韦拉平、喷昔洛韦、吡罗达韦、利巴韦林、甲磺酸沙奎那韦、利托那韦、盐酸索金刚胺、索立夫定、匍枝青霉菌素、司他夫定、替诺福韦、盐酸梯络龙、曲氟尿苷、盐酸伐昔洛韦、阿糖腺苷、磷酸阿糖腺苷、阿糖腺苷磷酸钠、替拉那韦、韦罗肟、扎西他滨、齐多夫定、净韦肟。
本发明另一个方面提供了一种治疗或预防冠状病毒科病毒所致疾病的药物组合物,其包括SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药。
在本发明的技术方案中,药物组合物的还包括药学上可接受的辅料。
在本发明的技术方案中,药物组合物的剂型为口服制剂、肺部吸入制剂、粘膜给药制剂、眼用制剂或注射剂。
在本发明的技术方案中,口服制剂选自颗粒剂、粉磨剂、丸剂、片剂、胶囊或口服液。
本发明另一个方面提供了SIRTINOL作为抗冠状病毒科病毒的消毒剂的用途。
本发明另一个方面提供了一种用于治疗冠状病毒科病毒所致疾病的方法,包括将治疗有效量的SIRTINOL或其药物学上可接受的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯或前药给药于受试者。
本发明另一个方面提供了一种用于预防受试者感染冠状病毒科病毒的方法,包括将治疗有效量的SIRTINOL或其药物学上可接受的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯或前药给药在感染前给予受试者。
有益效果
本发明首次证实了SIRTINOL对新冠肺炎新型冠状病毒抑制作用,其治疗指数高,半数有效浓度低;而且在染毒前施用SIRTINOL可有效增加防病毒的效果。SIRTINOL用作治疗抗新冠肺炎新型冠状病毒感染方面的有效药物。
附图说明
图1为新冠假病毒颗粒(SARS-2-S pseudotype particle)的生产与验证。
其中,(A)SARS-2-S蛋白可以成功在哺乳动物细胞中表达。(B)SARS-2-S假病毒颗粒具有S蛋白修饰。(C)SARS-2-S假病毒颗粒可成功侵染宿主细胞并整合报告基因。(D)SARS-2-S假病毒颗粒通过识别ACE2受体进入易感染细胞。(E)SARS-2-S假病毒颗粒能够侵染ACE2-GFP表达的人293T细胞,而不进入无ACE2表达的293T细胞。ACE2-GFP,绿色;Flag标签,红色,显示S蛋白;(F)SARS-2-S假病毒颗粒能够与ACE2受体结合,在细胞内的不同位置(细胞膜和细胞质)具有共定位信号。(G)SARS-2-S假病毒颗粒进入ACE2-GFP/293T细胞具有时间依赖性。
图2为SIRTINOL有效抑制假病毒颗粒侵染。免疫荧光染色法确定筛选出的临床药物对SARS-2-S假病毒颗粒侵染宿主细胞的抑制作用。假病毒颗粒侵染ACE2-GFP表达的293T细胞后,固定染色观察假病毒颗粒的细胞内定位。蓝色,DAPI;红色,Flag抗体标识S蛋白;绿色,ACE2-GFP信号。
具体实施方式
在本发明中,本文所用的术语治疗是指逆转、减轻、抑制该术语所适用的疾病或病症或者这些疾病或病症的一种或多种症状的进展,或预防这些疾病或病症或者这些疾病或病症的一种或多种症状。
如本文所用的术语“治疗有效量”是存在于本文所述组合物中的化合物1或其药学上可接受的盐的量,其是当通过所选择的施用途径施用这样的组合物时,在气道和肺的分泌物和组织中或者可选地在待治疗的受试者的血流中提供所需水平的药物,以产生预期的生理反应或所需的生物学效应。精确的量将取决于许多因素,例如组合物的比活性,所用的递送装置,组合物的物理特性,其预期用途,以及动物考虑因素例如疾病状态的严重程度等,并且本领域技术人员可以基于本文提供的信息容易地确定精确的量。
对于给药途径而言,本发明的活性成分通过适合于待治疗病症的任何途径施用。合适的途径包括口服、直肠、鼻、肺、局部(包括口腔和舌下)、阴道和肠胃外(包括皮下、肌内、静脉内、皮内、鞘内和硬膜外)等。可以理解的是,优选途径可以根据例如接收者的状况而变化。本发明化合物的优点是它们具有口服生物利用度并可以口服给药。
活性成分的有效剂量至少取决于所治疗病症的性质、毒性、化合物是否正在预防性使用(较低剂量)或针对活性病毒感染、递送方法和药物制剂,并且将由临床医师使用常规剂量递增研究确定。
在本发明的技术方案中,SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药与其他抗病毒药物制备的组合物作为活性成分在制备预防和/或治疗冠状病毒所致疾病的药物中的应用,对于上述方案中的两种以上的活性成分以单位剂型组合同时或顺序施用于患者。联合治疗可以作为同时或顺序方案施用。当按顺序施用时,组合可以是以两次或更多次施用给予。
在本发明的技术方案中,细胞为任意细胞,例如真核或者原核细胞,尤其指能够作为冠状病毒的宿主细胞,特别是包含ACE2受体的细胞。
为了使本发明的上述目的、特征和优点能够更加明显易懂,下面对本发明的具体实施方式做详细的说明,但不能理解为对本发明的可实施范围的限定。
实施例1新冠病毒S蛋白修饰的假病毒颗粒构建、生产与验证
为了模拟新冠肺炎病毒(SARS-CoV-2)利用S蛋白识别ACE2受体进行宿主细胞侵染的自然过程,构建了以复制缺陷型慢病毒为核心、修饰有SARS-2-S蛋白的假病毒颗粒。构建方法采用文章Evaluate severe acute respiratory syndrome coronavirus 2infectivity by pseudoviral particles,J Med Virol.2020年08月10日公布的方法。
首先,通过密码子优化方法,改造SARS-2-S蛋白的DNA序列而不改变其氨基酸序列,这有助于SARS-2-S在293T细胞中大量表达(图1A)。随后,利用实验室常用复制缺陷型HIV慢病毒作为假病毒颗粒的核心,在293T细胞中转染三质粒表达系统,将SARS-2-S修饰到假病毒颗粒的外膜上,形成SARS-2-S假病毒颗粒。通过免疫印迹法可以判断,此假病毒颗粒去除了原有的VSV-G包膜糖蛋白,替换成了新冠肺炎病毒的包膜糖蛋白SARS-2-S(图1B)。为了验证SARS-2-S假病毒颗粒的侵染效率,使假病毒颗粒携带有Luciferase报告基因,侵染宿主细胞293T或者ACE2/293T细胞。Luciferase细胞活性实验显示,SARS-2-S假病毒颗粒对ACE2/293T细胞具有高侵染性,侵染效率比293T细胞提高约100倍以上(图1C)。此外,也使用假病毒颗粒侵染具有内源性ACE2表达的猴肾上皮Vero-E6细胞,免疫荧光染色法发现SARS-2-S假病毒颗粒能够很好进入Vero-E6细胞;如果用siRNA将内源性ACE2受体敲降,能极大降低假病毒颗粒的侵染效率(图1D)。类似的,也使用ACE2-GFP过表达的293T作为宿主细胞观察假病毒颗粒的进入过程。免疫荧光染色结果显示,SARS-2-S能够有效进入ACE-GFP/293T细胞,而不进入无ACE2表达的293T细胞(图1E)。因此,以上结果证明,构建的SARS-2-S假病毒系统能够模拟S蛋白识别ACE2的自然过程,具有侵染活性。
通过激光共聚焦显微镜在高倍镜下进一步观察SARS-2-S假病毒颗粒的侵染过程,发现假病毒颗粒不仅定位于细胞膜上,也能够随ACE2受体进入细胞内,转运至细胞的核周区(perinuclear area)(图1F)。此外,SARS-2-S假病毒颗粒进入宿主细胞也具有时间依赖性,大约在2h后进入达到饱和期(图1G)。
实施例2细胞生物学平台筛选临床药物抑制SARS-2-S假病毒颗粒侵染
利用实施例1构建的SARS-2-S假病毒颗粒体外侵染模型(Luciferase报告系统和免疫荧光染色定位系统),进行SIRTINOL体外细胞生物学验证。在96孔板中接种ACE2-GFP稳转293T细胞,用不同浓度SIRTINOL药物预处理细胞2h后,再加入SARS-2-S假病毒颗粒侵染3h,随后去除上清更换为新鲜完全培养基。侵染40h后,利用Luciferase Assay System(Promega)裂解细胞并加入反应底物,用Glomax 96测定荧光素酶发光强度,此生物发光强度与病毒颗粒侵染效率成正比。
Luciferase活性检测结果显示,SIRTINOL具有明显的浓度依赖性效果,能够有效抑制SARS-2-S假病毒颗粒的侵染效率。SIRTINOL的EC50浓度约为82.9±61.1μM。
免疫荧光染色结果也显示,SIRTINOL在50μM浓度预处理宿主细胞2h,就能显著抑制SARS-2-S假病毒颗粒进入ACE2-GFP/293T(图2)。从图2结果来看,对照组中,假病毒颗粒大量进入细胞内,并定位于细胞核周围区,形成红色聚集区;给药组病毒颗粒大部分位于细胞膜和膜周围,说明SIRTINOL有效抑制了假病毒颗粒的侵入过程,将假病毒颗粒阻止在细胞膜上。
值得一提的是,由于免疫荧光染色需要对病毒颗粒进行成像,所以侵染使用的假病毒颗粒用量远远高于Luciferase报告实验,而后者更接近与生理状态下病毒在感染人体细胞时的用量。因此,Luciferase报告系统更能反应临床药物在生理条件下的抗病毒效果。这说明SIRTINOL具有较大抗新冠病毒感染潜力。该临床药物的作用通路和靶点在抑制新冠肺炎病毒侵染宿主细胞中的明确步骤,有极大的研究价值和药物筛选潜力。
Claims (11)
1.SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。
2.SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备阻止冠状病毒进入细胞的药物中的应用。
3.根据权利要求1或2所述的应用,其中所述的冠状病毒为新型冠状病毒SARS-Cov-2、SARS-CoV、HCoV 229E、NL63、OC43、HKU1和MERS-CoV。
4.根据权利要求1或2所述的应用,冠状病毒所致疾病为SARS-Cov-2、SARS-CoV、HCoV229E、NL63、OC43、HKU1或MERS-CoV任一病毒引起的肺炎或其并发症。
5.根据权利要求1或2所述的应用,SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药作为唯一活性成分。
6.根据权利要求1或2所述的应用,SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药与其他抗病毒药物制备的组合物作为活性成分。
7.根据权利要求6所述的应用,其他抗病毒药物选自更昔洛韦、阿昔洛韦、金刚烷胺、金刚乙胺、奥司他韦、阿巴卡韦、醋孟南、阿昔洛韦钠、阿德福韦、阿洛夫定、阿韦舒托、盐酸三环癸胺、阿拉诺丁、阿立酮、阿替韦啶甲磺酸酯、阿夫立定、西多福韦、西潘茶碱、恩曲他滨、盐酸阿糖胞苷、甲磺酸地拉韦啶、地昔洛韦、去羟肌苷、二噁沙利、依度尿苷、乙米韦林、依曲西他平、恩韦拉登、恩韦肟、贺普丁、泛昔洛韦、盐酸氯苯氢异喹、非西他滨、非阿尿苷、磷利酯、膦甲酸钠、膦乙酸钠、甘西洛维钠、碘苷、茚地那韦、乙氧丁酮醛、拉米夫定、洛布卡韦、洛德腺苷、洛匹那韦、盐酸美莫汀、甲红硫脲、那非那韦、奈韦拉平、喷昔洛韦、吡罗达韦、利巴韦林、甲磺酸沙奎那韦、利托那韦、盐酸索金刚胺、索立夫定、匍枝青霉菌素、司他夫定、替诺福韦、盐酸梯络龙、曲氟尿苷、盐酸伐昔洛韦、阿糖腺苷、磷酸阿糖腺苷、阿糖腺苷磷酸钠、替拉那韦、韦罗肟、扎西他滨、齐多夫定、净韦肟。
8.一种治疗或预防冠状病毒科病毒所致疾病的药物组合物,其包括SIRTINOL或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药作为活性成分;
优选地,药物组合物的还包括药学上可接受的辅料;
优选地,药物组合物的剂型为口服制剂、肺部吸入制剂、粘膜给药制剂、眼用制剂或注射剂。
9.根据权利要求8所述的药物组合物,药物组合物中还包括其他抗病毒药物;
优选地,其他抗病毒药物选自更昔洛韦、阿昔洛韦、金刚烷胺、金刚乙胺、奥司他韦、阿巴卡韦、醋孟南、阿昔洛韦钠、阿德福韦、阿洛夫定、阿韦舒托、盐酸三环癸胺、阿拉诺丁、阿立酮、阿替韦啶甲磺酸酯、阿夫立定、西多福韦、西潘茶碱、恩曲他滨、盐酸阿糖胞苷、甲磺酸地拉韦啶、地昔洛韦、去羟肌苷、二噁沙利、依度尿苷、乙米韦林、依曲西他平、恩韦拉登、恩韦肟、贺普丁、泛昔洛韦、盐酸氯苯氢异喹、非西他滨、非阿尿苷、磷利酯、膦甲酸钠、膦乙酸钠、甘西洛维钠、碘苷、茚地那韦、乙氧丁酮醛、拉米夫定、洛布卡韦、洛德腺苷、洛匹那韦、盐酸美莫汀、甲红硫脲、那非那韦、奈韦拉平、喷昔洛韦、吡罗达韦、利巴韦林、甲磺酸沙奎那韦、利托那韦、盐酸索金刚胺、索立夫定、匍枝青霉菌素、司他夫定、替诺福韦、盐酸梯络龙、曲氟尿苷、盐酸伐昔洛韦、阿糖腺苷、磷酸阿糖腺苷、阿糖腺苷磷酸钠、替拉那韦、韦罗肟、扎西他滨、齐多夫定、净韦肟。
10.一种用于治疗冠状病毒科病毒所致疾病的方法,包括将治疗有效量的SIRTINOL或其药物学上可接受的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯或前药给药于受试者。
11.一种用于预防受试者感染冠状病毒科病毒的方法,包括将治疗有效量的SIRTINOL或其药物学上可接受的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯或前药在感染冠状病毒前给予受试者。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011188930.6A CN114432283A (zh) | 2020-10-30 | 2020-10-30 | Sirtinol在制备预防和治疗冠状病毒的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011188930.6A CN114432283A (zh) | 2020-10-30 | 2020-10-30 | Sirtinol在制备预防和治疗冠状病毒的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114432283A true CN114432283A (zh) | 2022-05-06 |
Family
ID=81357462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011188930.6A Pending CN114432283A (zh) | 2020-10-30 | 2020-10-30 | Sirtinol在制备预防和治疗冠状病毒的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114432283A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012106509A1 (en) * | 2011-02-02 | 2012-08-09 | The Trustees Of Princeton University | Sirtuin modulators as virus production modulators |
-
2020
- 2020-10-30 CN CN202011188930.6A patent/CN114432283A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012106509A1 (en) * | 2011-02-02 | 2012-08-09 | The Trustees Of Princeton University | Sirtuin modulators as virus production modulators |
Non-Patent Citations (3)
Title |
---|
ABDO A.ELFIKY: "Anti-HCV, nucleotide inhibitors, repurposing against COVID-19", 《LIFE SCENECES》 * |
LAURA TEODORI等: "Pathways and microRNAs bioinformatics analyses identifying possible existing therapeutics for COVID-19 treatment", 《RESEARCH SQUARE》 * |
SEYEDEH ZAHRA MOUSAVI等: "A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection", 《INFECTION, GENETICS AND EVOLUTION》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2910136T3 (es) | Métodos de tratamiento de la gripe | |
US20190307722A1 (en) | Antiviral compositions for the treatment of infections linked to coronaviruses | |
Ashour et al. | A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval | |
CN107281210B (zh) | 阿奇霉素在抗冠状病毒感染中的应用 | |
CN111467363A (zh) | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 | |
CN111467338B (zh) | 焦谷氨酸在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用 | |
WO2020024719A1 (zh) | 二盐酸小檗胺在制备埃博拉病毒抑制剂中的应用 | |
CN113069446B (zh) | El102在制备治疗新型冠状病毒所致疾病的药物中的应用 | |
CN111407754A (zh) | 卡谷氨酸在制备预防和治疗冠状病毒的药物中的应用 | |
WO2021203704A1 (zh) | 杆菌酞a在制备预防和治疗冠状病毒的药物中的应用 | |
CN111467355B (zh) | 膦甲酸钠在制备预防和治疗冠状病毒的药物中的应用 | |
WO2022088037A1 (zh) | Sirtinol在制备预防和治疗冠状病毒的药物中的应用 | |
WO2022088047A1 (zh) | Itf2357在制备预防和治疗冠状病毒的药物中的应用 | |
Raghav et al. | Potential treatments of COVID-19: Drug repurposing and therapeutic interventions | |
CN107820423A (zh) | 用于预防和/或治疗上呼吸道感染的聚肌苷酸‑聚胞苷酸(聚(i:c))豌豆淀粉制剂 | |
CN113995752B (zh) | 一种小分子化合物在制备治疗新型冠状病毒所致疾病的药物中的应用 | |
WO2022088038A1 (zh) | Cay10603在制备预防和治疗冠状病毒的药物中的应用 | |
CN114432283A (zh) | Sirtinol在制备预防和治疗冠状病毒的药物中的应用 | |
CN114432305A (zh) | Cay10603在制备预防和治疗冠状病毒的药物中的应用 | |
WO2022088025A1 (zh) | 帕比司他在制备预防和治疗冠状病毒的药物中的应用 | |
CN114432287A (zh) | Itf2357在制备预防和治疗冠状病毒的药物中的应用 | |
CN112121044A (zh) | 氨来占诺用于制备抗肝炎病毒药物的用途 | |
CN114432303A (zh) | 帕比司他在制备预防和治疗冠状病毒的药物中的应用 | |
US20230256049A1 (en) | Materials and methods for the prevention and treatment of viral respiratory diseases | |
US20210353650A1 (en) | Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220506 |
|
RJ01 | Rejection of invention patent application after publication |